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Objective: The replacement of cytology with human papillomavirus (HPV) testing as the primary cervical screening test in England is imminent. In light of newly available evidence, we revised our previous estimates of the likely impact of primary HPV testing on incidence of cervical cancer.
Method and Results: Using screening data on women aged 25-64 diagnosed with cervical cancer in England between 1988 and 2012, we previously reported that 38.8% had a negative test 6 months to 6 years prior to diagnosis. However not all of these cancers would be prevented by HPV testing: for 1.0% the HPV positive test would come too late (within 18 months of diagnosis) to make a difference; (based on 79.9% sensitivity of HPV testing in cytology negative women) 7.6% will have a negative HPV test; and 2.0% will develop cancer despite a positive HPV test. Additionally we estimate that some women (equivalent to 4.3% of current incidence) whose cancers are currently prevented by cytology-based screening will have a false-negative HPV test.
Conclusion: Overall we estimate that 23.9% (95%CI: 19.3%-27.6%) of current cases in women invited for screening could be prevented. Based on 2013 cancer incidence statistics, absolute numbers could be reduced by 487 (95%CI 394 to 563) or 3.4 (95%CI 2.8 to 4.0) per 100,000 per year.






The intention to introduce primary HPV testing in the United Kingdom was recently announced by the UK National Screening Committee.1 In 2013 we estimated the impact of introducing HPV primary testing into the English cervical screening programme2, concluding that cervical cancer incidence in women aged 25-64 could be reduced by at most 32.6%, equivalent to 587 cancers (or 4.2 per 100,000 women) per year. Since then Ronco et al3 have published a pooled analysis of randomised controlled trials with cervical cancer as an outcome, comparing HPV testing with cytology. They found that among women with a negative cytology screening test at entry, the rate ratio for invasive cervical carcinoma was 0·30 (95% confidence interval (CI): 0·15–0·60). Here we update our previous estimates of the impact of primary HPV testing on incidence of cervical cancer in England, in light of this new evidence, and taking into account cancers that will be diagnosed despite a previous positive HPV test.

We used a population-based case-control study of prospectively recorded cervical screening data (from 1988 onwards) for women with cervical cancer (ICD-10 C53) diagnosed aged 25 to 64 in England between April 2007 and March 2012. Data on screening were abstracted from routinely recorded cervical cytology records held on the National Cervical Screening Call/Recall System. After linking, the data were pseudonymised before being transferred to us for analysis. Details of the National Audit of Cervical Cancer have been published previously.4,5

Previously we found that 38.8% (95% CI 37.8% to 39.8%) of women with cervical cancer had a negative cytology test resulting in routine recall (ie. that did not result in referral to colposcopy or early recall) between 6 months and 6 years prior to their diagnosis. Here we excluded the 1.0% of women whose only negative test within 6 years of diagnosis was within 18 months of diagnosis, on the grounds that a positive HPV test, together with a negative cytology test, would result in a repeat test a year later, and would probably not have led to the prevention (or even earlier diagnosis) of that cancer. 

We modelled the likely results of HPV testing using the following scenario:i) The overall sensitivity of English cytology to “pre-cancer” (ie. disease that would lead to a cancer diagnosis over the next 6 years) is 76.6% (95% CI 65.1%-85.1%)6; ii) there will be 70% (95% CI 40%-85%) fewer cancers in HPV negative women compared with cytology negative women ADDIN EN.CITE 3; iii)  in women who are cytology-positive, the sensitivity of HPV to pre-cancer will be 97.0% (95% CI 95.1%-98.9%).7 These values result in a 93.0% (95% CI 88.0%-98.0%) overall sensitivity of HPV testing for identifying women who have or would develop cervical cancer over the next 6 years, compared with an overall sensitivity of 96.5% (95% CI 93.0%-100.0%) in the previous publication (see table 1). 

Of the women with negative cytology 18 months to 6 years before diagnosis (37.8% of 8,774 cases in the audit), 79.9% (95% CI 74.8%-85.0%) would have been positive on the HPV test (18.7/23.4, see Table 1), and 7.6% (=37.8% × (1-0.799)) of cancers would be missed. 

We further took into account that a number of women will develop (or already have) cancer, despite a positive screen between 18 months and 6 years prior to diagnosis. From Table 1 we estimate that the sensitivity of HPV testing is 1.21 times that of cytology (ie. 93.0% vs 76.6%), or 21% (95% CI:18.1%-23.9%) higher. Using the National Audit of Cervical Cancer, we examined the number of cancers diagnosed 18 months to 6 years following an abnormal cytology result (defined as any result which was not negative or inadequate). We identified 833 women with such a test out of a total of 8,774 cancer cases (9.5%, 95% CI: 8.9%-10.1%). The proportion of cancers despite a positive HPV test (in women with a negative cytology test) due to failures in follow-up or in treatment of CIN would be expected to be an additional 21% of this figure (ie. of 9.5%), which is 2.0%.

As HPV testing is to become the sole primary screening test in the UK, it is necessary to take into account the proportion of cancers currently prevented by cytology-based screening which would be missed by HPV testing. We estimate this number to be equal to 4.3% of the current total number of cancers (see appendix 1). 

Taking all of these adjustments into account, we estimate that with HPV primary screening, the number of cervical cancers in women aged 25-64 in England might be reduced by 23.9% (corresponding to 38.8 – (1.0 + 7. 6 + 2.0 + 4.3)). Taking into account the uncertainty in the figures combined to reach this percentage, we estimate the 95% confidence interval to be: 19.3% to 27.6% (see appendix 2 for details).

In our original publication we estimated a maximum reduction of 587 cancers (or 4.2 per 100,000), using cancer statistics for England8 for 2010 to estimate absolute risks. The rate then in women aged 25-64 was 13.0 per 100,000 women, with a total of 1,801 cancers. The most recent data are for 20139 and show 2,039 cancers and a rate of 14.4 per 100,000 women. Applying a reduction of 23.9% to 2013 cancer incidence data yields a reduction of 487 (95% CI 394 to 563) cancers (or 3.4, 95% CI 2.8 to 4.0 per 100,000) in women aged 25-64 by introducing HPV primary testing. 

We believe that these updated estimates provide a more realistic estimate of the impact of switching to HPV testing in England. Nevertheless, other factors, such as vaccination (as of September 2015 the first vaccinated catch-up cohorts entered the screening programme) and falling screening coverage (particularly among older women) are not considered here, and are likely to have an impact on the effectiveness of HPV primary screening.






Table 1. Assumed proportions of human papillomavirus (HPV) and cytology test results in women who would develop cervical cancer over the following 6 years.
	HPV positive	HPV negative	Overall 
Cytology positive	74.3% (0.766£ x 0.970$)	2.3%	76.6%£
Cytology negative	18.7% 	4.7%	23.4%
Overall 	93.0%	7.0% ((1-0.70β) x 0.234)	100.0%







 ADDIN EN.REFLIST 1.	UK NSC recommendations include new bowel cancer screening test [press release]. 15 January 2016 2016.
2.	Castanon A, Landy R, Sasieni P. How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity? Journal of medical screening. 2013;20(2):99-103.
3.	Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32.
4.	Sasieni P, Castanon A. NHSCSP Audit of Invasive Cervical Cancer: National Report 2007-2011. Sheffield: 2012.
5.	NHS Cervical Screening Programme. Audit of Invasive Cervical Cancers. Sheffield2006 [updated December 200602Nov2015]. Available from: https://www.gov.uk/government/publications/cervical-screening-auditing-procedures (​https:​/​​/​www.gov.uk​/​government​/​publications​/​cervical-screening-auditing-procedures​).
6.	Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362(9399):1871-6.
7.	Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-82.
8.	Office for National Statistics. Cancer Statistics Registrations, England (Series MB1), No 41, 2012. London: 2014.







We estimate that cytology will have prevented 76.6% of cancers among screened women; with screening coverage of 76.8%: 588 (0.766x0.768x1000) out of 1000 potential cancers would be prevented by cytology, leaving 412 potential cancers. We assume that the sensitivity of HPV testing among women who test positive on cytology is 97.0%. Therefore 3.0% of the 588 (=18) cancers would progress to cancer with HPV testing instead of cytology. This represents 4.3% of the original number of cancers (18/412). 

The sensitivity of English cytology to pre-cancer is taken to be 76.6% (95% CI: 65.1%-85.1%), using the sensitivity to CIN2+ in the HART study.6 The sensitivity of HPV testing to pre-cancer in women with abnormal cytology is taken from the ARTISTIC study7 based on sensitivity to CIN3+. Combining the revealed and concealed arms, there were 303 women with abnormal cytology and CIN3+ in round 1, of whom 294 (97.0%; 95% CI: 95.1%-98.9%) were HPV positive.

Appendix 2
To calculate a confidence interval for the proportion of cervical cancers prevented by the introduction of HPV primary screening into the NHSCSP programme in England, we assigned a Gaussian distribution to the values used in the calculation (details in Table 2). The full calculation to obtain the 23.9% of extra cancers preventable by HPV primary testing is:
Β1-(Β1*(1- Β2))-(Β3* Β4)-((Β5* Β6)*(1- Β7)/(1-(Β5* Β6)))=0.239
We randomly generated 10,000 values for each of the point estimates in the formula above, assuming each parameter had a Gaussian distribution with the means and 95% confidence intervals given in Table 2. We combined them to produce 10,000 estimates of the reduction in cervical cancer by introducing HPV primary testing, selecting the 2.5th and 97.5th percentiles to give a 95% confidence interval. This resulted in a 95% confidence interval of 19.3% to 27.6%.

Table 2. Point estimates and range used in the estimation of confidence intervals for the proportion of extra cancers  preventable by the introduction of HPV testing in England
	Point estimate	95% CI	Definition
Β1	37.8%	36.8% - 38.8%	Proportion of women in the audit with a negative cytology 18mths to 6yrs prior to diagnosis of cervical cancer (3317/8774).
Β2	79.9%: 	74.8% - 85.0%	Proportion of women who are HPV+ given a negative cytology 18mths to 6yrs prior to diagnosis (.187/.234)
Β3	21%	18.1% - 23.9%	Additional women who would develop cancer despite a positive HPV test as a proportion of women who develop cancer despite having positive cytology (0.930/.766 - 1)
Β4	9.5%	8.9% - 10.1%	Proportion of women with cancer in the Audit who develop cancer despite a positive cytology test 18mths to 6yrs prior to diagnosis (833/8,774)
To calculate the 4.3% missed by HPV but prevented by cytology we use:
Β7	97.0%	95.1%  - 98.9%	Proportion of cytology positive women with CIN3 and an HPV positive test result (294/303 from Table 2 in ref (7))
Β5	76.8%	76.2% - 77.4%	Screening coverage observed in the Audit (13323/17341, from Table 1 in ref ())
Β6	76.6%: 	65.1% - 85.1%	Sensitivity of cytology to CIN2+.6
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